Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

rm using the effective interest method.

The foreign exchange gains and losses were nominal for each of Q1/08 and Q1/07.

Liquidity and Capital Resources

As of July 31, 2007, the Company had cash, cash equivalents and short-term investments of $12.8 million (April 30, 2007: $15.3 million) and the Company's net working capital was $12.1 million (April 30, 2007: $14.6 million). The $2.5 million decrease in net working capital from April 30, 2007 is primarily attributable to the cash loss of $2.4 million (loss excluding non-cash expenses: amortization, stock-based compensation and accretion of the convertible royalty participation units) for the three months ended July 31, 2007.

MIGENIX believes that its funds on hand at July 31, 2007, together with ongoing cost containment measures and expected interest income, are sufficient to provide for operations into the third quarter of calendar 2008 before funds received, if any, from existing or new license agreements, the exercise of warrants and options and future financing activities. The Company will continue advancing its highest priority programs while operating within an annual burn rate of $11 million to $13 million. The magnitude of spending in the Company's development programs will be dependent on the licensing status of the celgosivir program and results in the programs, and we may need to increase or decrease our annual burn rate in response to such results. MIGENIX is likely to need to raise additional funds in support of its operations and there is no assurance that such funds can be obtained

Outstanding Shares

There are currently 94,463,806 (July 31, 2007: 94,463,806; April 30, 2007: 94,237,205) common shares outstanding; 29,465 convertible royalty participation units (July 31, 2007 and April 30, 2007: 29,465); and 9,250,000 (July 31, 2007: 9,250,000; April 30, 2007: 9,350,000) preferred shares outstanding. In May 2007 the Company converted 50,000 Series A and 50,000 Series B
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today the formation of a Medical ... to the Company as it advances the Phase ... the treatment of cutaneous T-cell lymphoma (CTCL), a ...
(Date:11/15/2014)... (PRWEB) November 14, 2014 As ... is making significant investments in its network and ... modern cold chain and the complex requirements of ... ongoing focus on customized logistics and transportation, and ... of existing facilities. There will be an emphasis ...
(Date:11/15/2014)... 2014 Tapping into the human genome’s ... already proven itself as a viable market with multiple ... this opportunity with its current service offerings; its ... genealogical history for a nominal fee and provided sample. ... service and forthcoming myDNA Fitness program offer ...
(Date:11/15/2014)... 15, 2014 The report ... by End-User - Global Forecasts to 2019”, ... with an analysis and forecast of value ... Reverse Osmosis. Along with this, the value ... and regions are also discussed in the ...
Breaking Biology Technology:Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6QuickSTAT Announces Global Expansion Plan to Enhance Its Global Network and Cold Chain Logistics Capabilities for Life Sciences 2DNA Spectrum Begins the Search For a New Chief Executive Officer 2DNA Spectrum Begins the Search For a New Chief Executive Officer 3Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 2Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 3Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 4
... InSightec Ltd. announced,today that the U.S. Food and Drug ... 2000 MR-guided Focused Ultrasound,(MRgFUS) system for the treatment of ... the agency allows,physicians to treat up to 100% of ... up to half the fibroid tissue. , ...
... Control of the Entire Clinical Trial Registration Process ... Adhering to Changing Regulatory Requirements; Two Top-Ten Pharmaceutical ... Registration and Results Disclosure ProcessesNEW YORK, April 7 ... ), a leading services firm that provides ...
... Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) today ... clinical trial to evaluate the objective tumour response ... in patients with advanced cancers. , A total ... (melanoma (5), colorectal (4), gastric (1), pancreas (1), ...
Cached Biology Technology:FDA Approves Label Change for Non-Invasive Fibroid Treatment 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 3
(Date:11/11/2014)... Nov. 11, 2014  Forensicon, Inc., a ... pleased to announce the promotion of Yaniv Schiff ... Digital Forensics. In Schiff,s new role as Director, he ... of digital forensics examiners and provide leadership within the ... - http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined ...
(Date:11/7/2014)... Leading Biometric companies aim to provide ... online transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Google Inc. (NASDAQ: GOOG ), Microsoft ... EBAY ) and MasterCard Inc. (NYSE: MA) ... biometric authentication company focused on the growing mobile commerce is ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Approximately 55 percent of the horseradish produced in the ... the self-proclaimed "Horseradish Capital of the World." The product ... for gourmet and industrial use. But when crop sciences ... Illinois in 1999, he was told that growers had ...
... condition that causes frequent nighttime trips to the ... that shrinks the prostate, suggests a study being presented ... Meeting in New Orleans. The early findings hail from ... (PAE), which reduces blood flow to the prostate, thus ...
... Calif. , April 15, 2013  Medbox, Inc. (OTC ... industry specific consulting services and patented systems to various ... the standard bearer of corporate governance and transparency in the ... to its shareholders concerning the status of past, present, ...
Cached Biology News:Getting to the root of horseradish root problems 2Nonsurgical treatment turns back the clock, shrinks enlarged prostate 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 3Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 4Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 5
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Sulfadimethoxine (CH-2027)...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
... The EC3 Darkroom is designed for ... The EC3 systems offer direct control ... and darkroom settings by hand , A ... the best system for all fluorescent and ...
Biology Products: